Turkmenistan and La Roche Strengthen Partnership to Support Children with Rare Diseases

Geneva, The Gulf Observer: Representatives of the Permanent Mission of Turkmenistan to the United Nations Office in Geneva held a meeting with officials from the Swiss pharmaceutical company La Roche to review and advance joint healthcare initiatives aimed at supporting children affected by rare diseases.

According to a statement released by Turkmenistan’s Mission in Geneva on Tuesday, the discussions focused on the continuation and expansion of collaborative efforts to provide medical assistance to young patients suffering from conditions such as hemophilia and spinal muscular atrophy (SMA).

Under the current initiatives, essential medications are being delivered to patients, significantly enhancing their quality of life and mitigating the risk of long-term disability. Both parties reaffirmed their commitment to strengthening these efforts and ensuring sustained access to life-saving therapies.

The talks also addressed other areas of cooperation, including long-term access to treatment, professional training for medical personnel, and the transfer of diagnostic materials and technologies to Turkmenistan. These measures aim to improve early detection and comprehensive care for children with rare medical conditions.

Representatives of La Roche confirmed the company’s strong interest in maintaining a sustainable and long-term partnership with Turkmenistan, particularly in the field of pediatric care and rare diseases.

Founded in 1896, La Roche is one of the pioneers of the global pharmaceutical industry, with operations spanning Switzerland, Germany, and Italy. The company remains at the forefront of innovative therapies, including those targeting rare and chronic illnesses.

The meeting reflects Turkmenistan’s ongoing efforts to enhance international cooperation in the healthcare sector and improve the well-being of vulnerable populations through strategic global partnerships.